MX2017011857A - Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer. - Google Patents
Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer.Info
- Publication number
- MX2017011857A MX2017011857A MX2017011857A MX2017011857A MX2017011857A MX 2017011857 A MX2017011857 A MX 2017011857A MX 2017011857 A MX2017011857 A MX 2017011857A MX 2017011857 A MX2017011857 A MX 2017011857A MX 2017011857 A MX2017011857 A MX 2017011857A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- combination
- relates
- present
- cancers
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
Abstract
La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones de vacuna destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134253P | 2015-03-17 | 2015-03-17 | |
| GB201504502A GB201504502D0 (en) | 2015-03-17 | 2015-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| PCT/EP2016/055817 WO2016146751A1 (en) | 2015-03-17 | 2016-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011857A true MX2017011857A (es) | 2018-04-24 |
Family
ID=53016273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011857A MX2017011857A (es) | 2015-03-17 | 2016-03-17 | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10076560B2 (es) |
| EP (1) | EP3270952A1 (es) |
| JP (1) | JP6715856B2 (es) |
| KR (1) | KR102718168B1 (es) |
| CN (2) | CN113563456A (es) |
| AR (2) | AR121588A2 (es) |
| AU (4) | AU2016232140B2 (es) |
| BR (1) | BR112017019217A2 (es) |
| CA (1) | CA2979506A1 (es) |
| CR (3) | CR20210234A (es) |
| EA (1) | EA037783B1 (es) |
| GB (1) | GB201504502D0 (es) |
| MA (3) | MA46648B2 (es) |
| MX (1) | MX2017011857A (es) |
| PE (1) | PE20171515A1 (es) |
| SG (2) | SG11201706155XA (es) |
| TW (2) | TWI769586B (es) |
| UA (1) | UA123392C2 (es) |
| WO (1) | WO2016146751A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014110591A1 (en) | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| MY199500A (en) | 2015-03-17 | 2023-11-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| BR112018012374A2 (pt) | 2015-12-16 | 2018-12-04 | Gritstone Oncology, Inc. | identificação, fabricação e uso de neoantígeno |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| CN110167566A (zh) * | 2016-12-21 | 2019-08-23 | 弗莱德哈钦森癌症研究中心 | 治疗实体瘤细胞和逃避变体的支架 |
| CN111533797A (zh) * | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| SG11202000027WA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| KR102905054B1 (ko) | 2017-11-22 | 2025-12-29 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| JP7470640B2 (ja) * | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| JP7170737B2 (ja) | 2018-02-27 | 2022-11-14 | レイドス， インコーポレイテッド | Ｐｄ－１ペプチド阻害剤 |
| EP3765065A2 (en) * | 2018-03-16 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
| US12098179B2 (en) | 2018-03-16 | 2024-09-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| AU2020279371A1 (en) | 2019-05-22 | 2021-12-23 | Leidos, Inc. | LAG 3 binding peptides |
| US11975025B2 (en) | 2019-05-27 | 2024-05-07 | Immatics US, Inc. | Viral vectors and use thereof in adoptive cellular therapy |
| SG11202112561UA (en) | 2019-06-06 | 2021-12-30 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| PH12022552766A1 (en) * | 2020-04-29 | 2024-05-06 | Eg Biomed Co Ltd | Method for early detection, prediction of treatment response and prognosis of colorectal cancer |
| JP7560850B2 (ja) * | 2020-07-01 | 2024-10-03 | 学校法人関西医科大学 | 尿路系上皮腫瘍関連病変を検出するためのバイオマーカー |
| US11578102B2 (en) | 2020-07-31 | 2023-02-14 | Leidos, Inc. | LAG3 binding peptides |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022081426A1 (en) | 2020-10-12 | 2022-04-21 | Leidos, Inc. | Immunomodulatory peptides |
| CN112557347B (zh) * | 2020-11-12 | 2023-10-24 | 渤海大学 | 一种黏液层中乳糜粒子迁移模型的制备及检测方法 |
| CN112462066B (zh) * | 2020-12-03 | 2023-05-19 | 中南大学湘雅医院 | Fam3c蛋白及其特异性抗体在制备检测鼻咽癌试剂盒中的应用、试剂盒及其应用 |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| CN112760383B (zh) * | 2021-03-02 | 2023-07-21 | 上海欧易生物医学科技有限公司 | 应用于肺腺癌细胞亚群的一组qRT-PCR内参基因及其应用 |
| CN114163510B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| EP4408468A4 (en) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| KR102618065B1 (ko) * | 2021-12-10 | 2023-12-22 | 성균관대학교산학협력단 | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단 방법 |
| CN114214406A (zh) * | 2021-12-15 | 2022-03-22 | 天津医科大学总医院 | 一种用于评价肿瘤患者免疫治疗反应性和评估肿瘤预后的三联标志物及其应用 |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN119724622B (zh) * | 2024-11-25 | 2025-12-12 | 中国人民解放军总医院第五医学中心 | 一种评价ptt对胰腺癌治疗效果的方法、系统及设备 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610031A (en) * | 1993-10-27 | 1997-03-11 | The General Hospital Corporation | B1k chain of laminin and methods of use |
| US6316213B1 (en) * | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
| AU4158799A (en) * | 1998-06-06 | 1999-12-30 | Genostic Pharma Limited | Probes used for genetic filing |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| WO2001042270A1 (en) | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
| EP1242049A4 (en) | 1999-12-13 | 2005-01-05 | Epimmune Inc | VACCINE COMPOSITIONS AND ANTIGEN PEPTIDES ASSOCIATED WITH CLASS I HLA-A2 TUMOR |
| CN1469926A (zh) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
| WO2003010327A2 (en) * | 2001-02-21 | 2003-02-06 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| US20030021796A1 (en) * | 2001-05-04 | 2003-01-30 | Leszek Ignatowicz | Method of enhancing T cell immunity by selection of antigen specific T cells |
| JP2003321494A (ja) * | 2002-02-26 | 2003-11-11 | Daiichi Fine Chemical Co Ltd | プロｍｍｐ−７の活性化調節方法 |
| EP1531848A4 (en) * | 2002-06-10 | 2007-03-28 | Vaccinex Inc | DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE |
| CA2500687A1 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003298014A1 (en) * | 2002-12-04 | 2004-06-23 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| ATE462003T1 (de) | 2004-03-31 | 2010-04-15 | Int Inst Cancer Immunology Inc | Aus wt1 stammende krebsantigenpeptide |
| PT1760089E (pt) * | 2005-09-05 | 2009-10-19 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena |
| GB0611116D0 (en) * | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
| HUE025636T2 (en) * | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| EP2127664A1 (en) * | 2008-02-15 | 2009-12-02 | Max-Delbrück-Centrum | Change of the load state of MHC molecules by dipeptides |
| CN102131919B (zh) * | 2008-03-31 | 2017-05-03 | 东方酵母工业株式会社 | 一种增殖多能性干细胞的方法 |
| DK2119726T5 (en) * | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| US8568996B2 (en) * | 2008-10-21 | 2013-10-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | MMP activation peptide detection in biological samples |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US10706955B2 (en) * | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2012178087A1 (en) * | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| WO2013033609A2 (en) * | 2011-08-31 | 2013-03-07 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
| US20140065620A1 (en) * | 2011-12-29 | 2014-03-06 | Mayo Foundation For Medical Education And Research | Nucleic acids for detecting breast cancer |
| TWI819228B (zh) * | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| CN104163862B (zh) * | 2013-12-04 | 2017-02-08 | 魏敏杰 | 与人mhc‑i类分子结合的grp78多肽表位 |
| CN104306976A (zh) * | 2014-04-26 | 2015-01-28 | 深圳市康尔诺生物技术有限公司 | 一种高效的肿瘤个体化免疫治疗方法及其应用 |
-
2015
- 2015-03-17 GB GB201504502A patent/GB201504502D0/en not_active Ceased
-
2016
- 2016-03-17 BR BR112017019217-9A patent/BR112017019217A2/pt not_active Application Discontinuation
- 2016-03-17 US US15/073,528 patent/US10076560B2/en active Active
- 2016-03-17 AU AU2016232140A patent/AU2016232140B2/en not_active Ceased
- 2016-03-17 CR CR20210234A patent/CR20210234A/es unknown
- 2016-03-17 MA MA46648A patent/MA46648B2/fr unknown
- 2016-03-17 SG SG11201706155XA patent/SG11201706155XA/en unknown
- 2016-03-17 PE PE2017001485A patent/PE20171515A1/es unknown
- 2016-03-17 CA CA2979506A patent/CA2979506A1/en active Pending
- 2016-03-17 UA UAA201707771A patent/UA123392C2/uk unknown
- 2016-03-17 WO PCT/EP2016/055817 patent/WO2016146751A1/en not_active Ceased
- 2016-03-17 EP EP16710223.5A patent/EP3270952A1/en active Pending
- 2016-03-17 MA MA46647A patent/MA46647A1/fr unknown
- 2016-03-17 TW TW109140068A patent/TWI769586B/zh active
- 2016-03-17 EA EA201791853A patent/EA037783B1/ru unknown
- 2016-03-17 SG SG10202001404VA patent/SG10202001404VA/en unknown
- 2016-03-17 CR CR20210233A patent/CR20210233A/es unknown
- 2016-03-17 CN CN202110838669.8A patent/CN113563456A/zh active Pending
- 2016-03-17 MX MX2017011857A patent/MX2017011857A/es unknown
- 2016-03-17 TW TW105108310A patent/TWI726872B/zh active
- 2016-03-17 KR KR1020177025935A patent/KR102718168B1/ko active Active
- 2016-03-17 JP JP2017547530A patent/JP6715856B2/ja active Active
- 2016-03-17 CN CN201680015234.0A patent/CN107428810B/zh active Active
- 2016-03-17 MA MA40713A patent/MA40713A1/fr unknown
- 2016-03-17 CR CR20170419A patent/CR20170419A/es unknown
-
2018
- 2018-01-12 US US15/869,471 patent/US10357551B2/en active Active
-
2020
- 2020-08-18 AU AU2020220073A patent/AU2020220073B2/en not_active Ceased
- 2020-08-18 AU AU2020220072A patent/AU2020220072B2/en not_active Ceased
- 2020-08-18 AU AU2020220070A patent/AU2020220070B2/en not_active Ceased
-
2021
- 2021-02-24 AR ARP210100473A patent/AR121588A2/es unknown
- 2021-02-24 AR ARP210100472A patent/AR121587A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011857A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer. | |
| MX2023014146A (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer epitelial de ovario y otros tipos de cancer. | |
| CO2018003860A2 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de mama y otros tipos de cáncer | |
| CO2018002202A2 (es) | Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
| CO2017012891A2 (es) | Péptidos y combinaciones de péptidos para la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer | |
| MX2022005060A (es) | Novedosos peptidos y combinaciones de peptidos para usarse en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon no microcitico (nsclc) y otros canceres. | |
| CO2018010009A2 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
| CO2018000245A2 (es) | Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| CO2018003659A2 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer | |
| CR20200561A (es) | PÉPTIDOS Y COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL LINFOMA NO HADGKINIANO (LNH) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0346) | |
| CR20200592A (es) | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295) | |
| CR20180001A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer. | |
| CR20180245A (es) | Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer | |
| CR20180051A (es) | Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer. | |
| CR20180398A (es) | Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga y otros tipos de cáncer | |
| CO2019008008A2 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer | |
| CO2018002902A2 (es) | Péptidos y combinaciones de péptidos para el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| MX2018014316A (es) | Nuevos peptidos y nueva combinacion de peptidos como dianas y para el uso en la inmunoterapia contra el cancer de vesicula biliar y el colangiocarcinoma, asi como otros tipos de cancer. | |
| CO2018012294A2 (es) | Inmunoterapia contra el melanoma y otros tipos de cáncer | |
| CO2018004869A2 (es) | Péptidos y combinación de péptidos para inmunoterapia contra varios tipos de cáncer | |
| CO2017010830A2 (es) | Péptidos y combinaciones de péptidos y de soportes | |
| CL2023001324A1 (es) | Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres | |
| CL2017002346A1 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| CO2018006023A2 (es) | Epítopos celulares y combinaciones de epítopos celulares para inmunoterapia del mieloma y de otros tipos de cáncer |